---
title: 'Classification, risk stratification and response assessment in myelodysplastic
  syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International
  Consortium for MDS (icMDS)'
date: '2023-09-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37704469/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230914180856&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: The guidelines for classification, prognostication, and response assessment
  of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In
  this report on behalf of the International Consortium for MDS (icMDS) we summarize
  these developments. We first critically examine the updated World Health Organization
  (WHO) classification and the International Consensus Classification (ICC) of MDS.
  We then compare traditional and molecularly based risk MDS risk assessment tools.
  Lastly, ...
disable_comments: true
---
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, ...